UBS Cuts Price target on Marvell Technology (MRVL) Given Additional Details on Delayed 2Q16 Results

B. Riley Downgrades Marvell (MRVL) to Neutral

B. Riley downgraded Marvell (NASDAQ: MRVL) from Buy to Neutral with a price target of $10.00 (from $17.00).

For an analyst ratings summary and ratings history on Marvell click here. For more ratings news on Marvell click here.

Shares of Marvell closed at $8.84 yesterday.

Morgan Stanley Downgrades Marvell (MRVL) to Equalweight

Morgan Stanley downgraded Marvell (NASDAQ: MRVL) from Overweight to Equalweight with a price target of $9.50 (from $17.50).

For an analyst ratings summary and ratings history on Marvell click here. For more ratings news on Marvell click here.

Shares of Marvell closed at $8.84 yesterday.

Top 10 News for 9/8 - 9/11: Apple Debuts Key Next-Gen Products; United Air Chief Resigns; Reserve Drawdown Hits Markets

1. On Wednesday afternoon, Apple (Nasdaq: AAPL) announced a series of new and updated products on Wednesday, including:iPhone 6s and iPhone 6s Plus. Click here for more color.Apple TV. Click here for more color.iPad Pro.... More

Marvell's (MRVL) Announcement Described One of Most 'Cryptic' in 20yrs - Cowen

Cowen maintained an Outperform rating on Marvell (NASDAQ: MRVL) but cut its price target to $14.00 (from $16.00). Analyst Timothy Arcuri said the company's press release related to accounting issues was "one of the most cryptic releases we have seen in 20yrs on the sell... More

Notable 52-Week Highs and Lows 9/11: (CNCE) (INCY) (MRTX) High; (MRVL) (FNSR) (ZUMZ) Low

52-Week High:Concert Pharmaceuticals (Nasdaq: CNCE) $19.64. Concert Pharmaceuticals gaining after it presentation at the Baird 2015 Healthcare Conference yesterday. The company will also be presenting at the Ladenburg Thalmann 2015 Healthcare Conference on September 29th.

Incyte Corporation (Nasdaq: INCY) $131.00. Incyte continuing higher on speculation that it might be a takeover target for Gilead Sciences.

Mirati Therapeutics (Nasdaq: MRTX) $42.88. Mirati Therapeutics adding to gains... More

Marvell's (MRVL) Price Target Reduced to $10 at Deutsche Bank

Deutsche Bank maintained a Hold rating on Marvell (NASDAQ: MRVL) and reduced its price target to $10.00 (from $14.00). Earlier Marvell reported disappointing preliminary Q2 results and an audit committee investigation.

Commenting on the news, analyst Ross Seymore said, "MRVL reported preliminary F2Q16 GAAP results and announced an independent investigation of certain F2Q16 rev rec... More

FBR Capital Downgrades Marvell (MRVL) to Market Perform

FBR Capital downgraded Marvell (NASDAQ: MRVL) from Outperform to Market Perform with a price target of $9.00.

Analyst Chris Rolland commented, "On Friday morning, September 11, Marvell reported worse-than-expected C2Q15 results and failed to offer 3Q15 guidance as the company announced an... More

Unusual 11 Mid-Day Movers 9/11: (ACET) (VVUS) (PGI) Higher; (CHKE) (ZUMZ) (EFOI) Lower

Cherokee (Nasdaq: CHKE) 34.0% LOWER; reported Q2 EPS of $0.22, $0.02 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $8.5 million versus the consensus estimate of $8.62 million. Cherokee Global Brands also announced that Target Corporation has elected not to renew the license of the Cherokee brand in the US, which will expire at the end of its current term on January 31, 2017.

Zumiez, Inc. (Nasdaq: ZUMZ) 27.7% LOWER; reported Q2 EPS of $0.11, $0.01 worse than the analyst estimate of $0.12. Revenue... More

RBC Capital Cuts Price Target on Marvell Technology (MRVL) to $9 Following 1Q16 Preliminary Results

RBC Capital maintained a Sector Perform rating on Marvell (NASDAQ: MRVL), and cut the price target to $9.00 (from $13.00), following announced preliminary financial results for 1Q16. Analyst Mitch Steves said that the results suggests incremental softness from a demand perspective.

Steves commented,... More

UPDATE: Brean Capital Downgrades Marvell (MRVL) to Hold

(Updated - September 11, 2015 9:44 AM EDT)

(update reflects downgrade to hold)

Brean Capital downgraded Marvell (NASDAQ: MRVL) from Buy to Hold on account investigation.

Analyst Mike Burton commented, "Marvell announced preliminary GAAP results and an Audit Committee investigation into accounting and... More

Pre-Open Stock Movers 09/11: (LTRE) (PGI) (ZSPH) Higher; (CHKE) (MRVL) (ZUMZ) Lower (more...)

Learning Tree International (NASDAQ: LTRE) 70% HIGHER; Mill Road offers to buy company for $1.80/share.

Cherokee (NASDAQ: CHKE) 34.4% LOWER; reported Q2 EPS of $0.22, $0.02 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $8.5 million versus the consensus estimate of $8.62 million. Cherokee Global Brands also announced that Target Corporation has elected not to renew the license of the Cherokee brand in the US, which will expire at the end of its... More

Needham & Company Downgrades Marvell (MRVL) to Hold

Needham & Company downgraded Marvell (NASDAQ: MRVL) from Buy to Hold amid the audit committee investigation.

Analyst N. Quinn Bolton commented, "When Marvell delayed the release of its F2Q16 results three weeks ago, we were hopeful the delay was a sign the... More

Susquehanna Downgrades Marvell (MRVL) to Neutral Amid Accounting Investigation

Susquehanna downgraded Marvell (NASDAQ: MRVL) from Positive to Neutral with a price target of $9.00 (from $16.00) amid accounting investigation.

Analyst Chris Caso commented, "We are downgrading MRVL from a Positive to a Neutral rating amid the companys disclosure this morning of an investigation into its accounting and... More

Marvell Technology (MRVL) Misses Q2 GAAP Loss of 74c/Share

Marvell Technology (NASDAQ: MRVL) reported Q2 EPS of ($0.74), $0.85 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $711 million versus the consensus estimate of $725.01 million.

The Company also announced that the Audit Committee of the Companys Board of Directors is conducting an independent investigation of certain accounting and internal control matters in the second quarter of fiscal 2016. Senior management has cooperated fully with the Audit Committees investigation, and is fully committed to supporting the Audit Committee in this process.

The investigation consists of a review of certain... More

Marvell Technology (MRVL) Will Delay 10-Q Filing; Notes Probe into Internal Controls

Marvell Technology (Nasdaq: MRVL) has determined that it is unable to file its Quarterly Report on Form 10-Q for the quarter ended August 1, 2015 (Quarterly Report) within the prescribed time period without unreasonable effort or expense for the reasons described below.

As disclosed in the Companys press release dated September 11, 2015, the Audit Committee of the Companys Board of Directors is conducting an independent investigation of certain accounting and internal control matters in the second quarter of fiscal 2016. The investigation consists of a review of certain revenue recognition issues in the second quarter of fiscal... More